An open-label study of a new formulation of Viracept [nelfinavir] to assess gastrointestinal tolerability in patients with HIV-1 infection.

Trial Profile

An open-label study of a new formulation of Viracept [nelfinavir] to assess gastrointestinal tolerability in patients with HIV-1 infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Nelfinavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 23 Feb 2010 Last checked against Roche record.
    • 23 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top